Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Product

Terms/Details (Date)

Accelrys Inc. (subsidiary of Pharmacopeia Inc.; PCOP)

Jubilant Biosys (India)

Jubilant's ChemBioBase, a database of kinase inhibitors

Accelrys agreed to be the exclusive distributor of the database, making it a module in its Catalyst 4.9 product suite (12/22)

AEterna Laboratories Inc. (Canada; TSE:AEL)

Produtos Roche QFSA (Brazilian unit of Roche)

Deal for the marketing in Brazil of Impavido (miltefosine), an oral therapy for leishmaniasis

Roche will support AEterna unit Zentaris GmbH in registration efforts in Brazil, and would market the product there; terms were not disclosed (2/2)

Atria Genetics Inc.*

Abbott Laboratories

For tests that define human leukocyte antigens used to identify donors for bone marrow transplantation

Abbott gets exclusive rights outside the U.S. to Atria's AlleleSEQR HLA DNA sequencing-based typing products, and exclusive rights to HLA analyte-specific reagents in the U.S.; terms were not disclosed (1/12)

Atrix Laboratories Inc. (ATRX)

Han All Pharmaceutical Co. Ltd. (Korea)

Han All gained distribution rights in Korea to Eligard (leuprolide acetate for injectable suspension)

Atrix would get royalties on any sales and manufacturing payments; Han All is responsible for all regulatory actions in Korea (1/28)

Auxilium Pharmaceuticals Inc.*

Bayer Inc.

Distribution agreement for marketing of Auxilium's Testim 1% testosterone gel in Canada

Auxilium will file for approval in Canada and Bayer would market the product there; terms were not disclosed (2/2)

BioMarin Pharmaceuticals Inc. (BMRN)

Merck KGaA (Germany)

Phenoptin, an enzyme cofactor and second-generation oral form of tetrahydrobiopterin

Merck subsidiary Merck Eprova AG will manufacture product for clinical trials, which are expected to start in 2004 (11/20)

Cambridge Antibody Technology Group plc (UK; LSE:CAT)

Lonza Group Ltd.

Companies extended November 2001 agreement, confirming that Lonza Biologics will manufacture clinical-grade antibodies for CAT through 2006

The deal encompasses both ongoing and future products; terms were not disclosed (1/20)

Discovery Laboratories Inc. (DSCO)

Laureate Pharma LP

Laureate will provide manu- facturing services to support drugs from Discovery

As part of the deal Discovery transferred its existing manufacturing equipment to Laureate's microparticle manufacturing facility (1/21)

Diversa Corp. (DVSA)

BASF Pharma (Germany) 

Enzyme for the biocatalytic synthesis of a pharmaceutical intermediate

BASF will apply the biocatalyst to one of its processes to synthesize a chiral intermediate; it is the first license taken from their 2002 collaboration; terms were not disclosed (12/1)

Genentech Inc. (NYSE:DNA)

Lonza Group Ltd. (Switzerland)

Commercial quantities of Genentech's Rituxan

Lonza will manufacture product at its facility in Portsmouth, N.H.; terms were not disclosed (12/16)

Hemispherx Biopharma Inc. (AMEX:HEB)

Fujisawa Deutschland GmbH (Germany)

Fujisawa got an option to distribute Hemispherx's Ampligen in Germany, Austria and Switzerland

Fujisawa paid |400,000 for the option and would pay additional undisclosed fees and milestone payments if it exercises the option (2/18)

ID Biomedical Corp.* (Canada)

Dynport Vaccine Co.

Second-generation, subunit plague vaccine

ID is getting about $4.5M in additional funding under their contract for process development and manufacturing activities related to production of a recombinant plague antigen (12/3)

InKine Pharmaceutical Co. Inc. (INKP)

Pharmatel (Australia)

Marekting deal for InKine's Visicol in Australia and New Zealand

Pharmatel paid an undisclosed license fee and will pay royalties to InKine on sales in those countries (1/27)

InKine Pharmaceutical Co. Inc. (INKP)

Sigma-Tau Pharmaceuticals Inc.

Co-promotion deal under which InKine will sell Sigma-Tau's VSL#3 in the second position behind Visicol

InKine could receive $1.5M over the one- year term; additional incentives are built into the deal (12/10)

Inspire Pharmaceuticals Inc. (ISPH)

Allergan Inc.

Elestat (epinastine HCL ophthalmic solution 0.05%) in ophthalmic indications

Allergan will co-promote the product, which was approved in October; Inspire will make an up-front payment and Allergan will pay royalties on sales; they also reworked agreement on Restasis to provide for lower royalties paid to Inspire (12/8)

MediGene AG* (Germany)

Yamanouchi Pharmaceutical Co. Ltd. (Japan)

MediGene named Yamanouchi its European marketing partner for the Eligard (Leuprogel) line of prostate cancer products

MediGene had gained rights from Atrix Laboratories Inc.; terms were not disclosed (1/14)

Nabi Biopharmaceuticals
(NABI)

Kamada Ltd. (Israel)

Distribution agreement for Nabi-HB (hepatitis B immune globulin)

Kamada will coordinate regulatory actions and sell the product in Israel, Argentina, Brazil, Mexico and India (2/6)

NexMed Inc. (NXMD)

CJ Corp. (South Korea)

NexMed's Femprox, a cream treatment for female sexual arousal disorder

CJ will develop and seek approval of the product in Korea, and would pay royalties to NexMed (2/19)

TeGenero AG* (Germany)

Boehringer Ingelheim GmbH (Germany)

CD28-SuperMAB (TGN1412), a humanized monoclonal antibody

BI will be responsible for process development and manufacturing of material for clinical trials (11/17)

Transkaryotic Therapies Inc. (Australia)

Orphan Australia Fabry's disease

TKT's Replagal (agalsidase alfa) for the treatment of in Australia and New Zealand for 15 years

Orphan Australia will have exclusive marketing and distribution rights to Replagal (TKTX) (12/30)

VaxGen Inc. (VXGN)

Chemo-Sero-Therapeutic Research Institute (Japan)

Attenuated smallpox vaccine LC16m8

VaxGen will purchase vaccine in bulk form and complete secondary manufacture; the deal covers sales in the U.S. but could be expanded (12/2)

Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; LSE = London Stock Exchange.; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange.